miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases

Qinhong Xu; Pei Li; Xin Chen; Liang Zong; Zhengdong Jiang; Ligang Nan; Jianjun Lei; Wanxing Duan; Dong Zhang; Xuqi Li; Huanchen Sha; Zheng Wu; Qingyong Ma; Zheng Wang

doi:10.18632/oncotarget.3686

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases

Qinhong Xu, Pei Li, Xin Chen, Liang Zong, Zhengdong Jiang, Ligang Nan, Jianjun Lei, Wanxing Duan, Dong Zhang, Xuqi Li, Huanchen Sha, Zheng Wu, Qingyong Ma and Zheng Wang _

PDF | HTML | How to cite

Oncotarget. 2015; 6:14153-14164. https://doi.org/10.18632/oncotarget.3686

Metrics: PDF 2445 views | HTML 2514 views | ?

Abstract

Qinhong Xu1,*, Pei Li1,2,*, Xin Chen1, Liang Zong1, Zhengdong Jiang1, Ligang Nan1, Jianjun Lei1, Wanxing Duan1, Dong Zhang1, Xuqi Li3, Huanchen Sha1, Zheng Wu1 Qingyong Ma1 and Zheng Wang1

1 Department of Hepatobiliary Surgery, First Affiliated Hospital Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi, China

2 Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China

3 Department of General Surgery, First Affiliated Hospital Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi, China

* These authors have contributed equally to this work

Correspondence to:

Zheng Wang, email:

Keywords: miR-221/222, pancreatic cancer, matrix metalloproteinases

Received: December 20, 2014 Accepted: March 03, 2015 Published: March 29, 2015

Abstract

MicroRNAs are involved in the initiation and progression of pancreatic cancer. In this study, we showed that miR-221/222 is overexpressed in pancreatic cancer. MiR-221/222 overexpression significantly promoted pancreatic cancer cell proliferation and invasion while inhibiting apoptosis. The expression of the matrix metalloproteinases (MMPs) MMP-2 and MMP-9 was increased in miR-221/222 mimic-transfected pancreatic cancer cells. Validation experiments identified TIMP-2 as a direct target of miR-221/222. These data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3686

Publication Alerts

Research Papers:

miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases

Abstract